Professor Xiaofei Liang

High Magnetic Field Lab, CAS
P.O. Box 1110, 350 Shushanhu Road, Hefei, 230031

Tel: 0551-65591485
Email: XiaofeiLiang@hmfl.ac.cn

XiaofeiLiang2005@yahoo.com

 

 

 

EDUCATION BACKGROUND

2010.12-2013.09: Duke University, Department of Chemistry, Postdoctoral Follow

Research focus: medicinal chemistry of LpxC inhibitors as novel antibiotics.

2008.09-2010.09: Exchange Student

Research focus: design, synthesis, and structure-activity relationships study of new N-Hydroxyamide derivatives as LpxC inhibitors.

Advisor: Prof. Pei Zhou; Prof. Eric J. Toone

2005.09-2010.12: Jilin University Ph. D. in Organic Chemistry

Dissertation Title: Design, Synthesis, and Structure-Activity Relationships Study of New N-Hydroxyamide Derivatives as UDP-(3-O-acyl)-N-acetylglucosamine Deacetylase (LpxC) Inhibitors.

Advisor: Prof. Yaoxian Li

2000.09-2005.09： Changchun Normal University B.S. in Chemistry

Dissertation Title: Synthesis and Optimization methyl salicylate catalyzed by Nd2O3

 

AWARDS

China Scholarship Council as a visiting scholar in Duke University (2008.09-2010.09); Outstanding Undergraduate Student, 1st Overall Prize, Changchun Normal University (2004); Excellent Undergraduate Student, Changchun Normal University(2004).

 

RESEARCH EXPERIENCE

Duke University/Jilin University

Advisor: Prof. Yaoxian Li; Prof. Eric J. Toone; Prof. Pei Zhou

My research project was mainly about the structure-based drug design targeting LpxC, a key enzyme in the biosynthesis of lipopolysaccharide. Based on the crystal structure of LpxC in complex with a lead compound, we designed and synthesized a series of novel hydroxamic acid derivatives to improve the potency and spectrum of the lead compounds by targeting multiple epitopes of the active site and by fine-tuning the flexibility of compound scaffold. (2008.09-2013.09)

Jilin University

Advisor: Prof. Yaoxian Li;

Design and synthesis of small fluorescent molecules in doped polymers, and the electrospinning of nano-composite fiber. Synthesis and optimization of the derivatives of vanillin, iso-vanillin and heliotropin. Optimization of the dimethylaniline from p-amino dimethylaniline. (2005.08-2008.09)

 

PUBLICATIONS

  1. Xiaofei Liang ,# Fengchao Lv,# Beilei Wang,# Kailin Yu,# Hong Wu, Ziping Qi, Zongru Jiang, Cheng Chen, Aoli Wang, Weili Miao, Wenchao Wang, Zhenquan Hu, Juan Liu, Xiaochuan Liu, Zheng Zhao, Li Wang, Shanchuan Zhang, Zi Ye, Chu Wang, Tao Ren, Yinsheng Wang, Qingsong Liu,* Jing Liu*, Discovery of 2((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor, J. Med. Chem. 2017, 60(5): 1793–1816.
  2. Marie Titecat, Xiaofei Liang, Chul-Jin Lee, Audrey Charlet, Didier Hocquet, Thierry Lambert, Jean-Marie Page`s, Rene´ Courcol1, Florent Sebbane1, Eric J. Toone, Pei Zhou, Nadine Lemaitre1*, High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors, J. Antimicrob. Chemother. 2016, 71(10): 2874-2882.
  3. Xiaochuan Liu#, Aoli Wang#, Xiaofei Liang#, Juanjuan Liu#, Fengming Zou#, Cheng Chen, Zheng Zhao, Yuanxin Deng, Hong Wu,Ziping Qi, Beilei Wang, Li Wang, Feiyang Liu,Yunhe Xu, Wenchao Wang, Feiyang Liu, Stacey M. Fernandes, Richard M. Stone,Ilene A. Galinsky, Jennifer R. Brown,Teck Peng Loh, James. D. Griffin, Shanchun Zhang, Ellen L. Weisberg, Xin Zhang*, Jing Liu*, Qingsong Liu*, Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies, Oncotarget 2016, 7(33): 53515-53525.
  4. Xiaofei Liang, Gopalaswamy, Ramesh*, Navas III, Frank; Toone, Eric; Zhou, Pei*, An Efficient and Scalable Synthesis of the Difluoromethyl-allo-threonyl hydroxamate-based LpxC Inhibitor LPC-058, J. Org. Chem. 2016, 81(10): 4393−4398.
  5. Xiaochuan Liu#, Aoli Wang#, Xiaofei Liang#, Cheng Chen#, Juanjuan Liu, Zheng Zhao, Hong Wu, Yuanxin Deng, Li Wang, Beilei Wang, Jiaxin Wu, Feiyang Liu, Stacey M. Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Jennifer R. Brown, James D. Griffin, Shanchun Zhang, Teckpeng Loh, Xin Zhang, Wenchao Wang*, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu*, Characterization of Selective and Potent PI3Kδ Inhibitor (PI3KD-IN-015) for B-Cell Malignances , Oncotarget 2016, 7(22): 32641-32651.
  6. Chul-Jin Lee#, Xiaofei Liang#, Qinglin Wu#, Javaria Najeeb#, Jinshi Zhao, Ramesh Gopalaswamy, Marie Titecat, Florent Sebbane, Nadine Lemaitre, Eric J. Toone, Pei Zhou*, Drug Design from the Cryptic Inhibitor Envelope, Nature Communications 2016, 7: 10638.
  7. Xiaofei Liang#, Xiaochuan Liu#, Beilei Wang#, Fengming Zou#, Aoli Wang, Shuang Qi, Cheng Chen, Zheng Zhao, Wenchao Wang, Ziping Qi, Fengchao Lv, Li Wang, Shanchun Zhang, Qingsong Liu*, Jing Liu* Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide(CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia, J. Med. Chem. 2016, 59(5): 1984−2004.
  8. Chul-Jin Lee, Xiaofei Liang, Ramesh Gopalaswamy, Eugene Park, Eric J. Toone, Pei Zhou*, Structural Basis of the Promiscuous Inhibitor Susceptibility of E. coli LpxC, ACS Chem. Biol. 2014, 9(1): 237-46.
  9. Xiaofei Liang#, Chul-Jin Lee#, Jinshi Zhao, Eric J. Toone, Pei Zhou*, Synthesis, structure and antibiotic activity of aryl-substituted LpxC inhibitors, J. Med. Chem. 2013, 56(17): 6954–6966.
  10. Yesu Feng#, Thomas Theis#, Xiaofei Liang, Qiu Wang, Pei Zhou, Warren S. Warren*, Storage of Hydrogen Spin Polarization in Long-Lived 13C2 Singlet Order and Implications for Hyperpolarized Magnetic Resonance Imaging, J. Am. Chem. Soc. 2013, 135(26): 9632−9635.
  11. Bidong D. Nguyen, Doreen Cunningham, Xiaofei Liang, Xin Chen, Eric J. Toone, Christian R. H. Raetz, Pei Zhou, Raphael H. Valdivia*, Lipooligosaccharide is required for the generation ofinfectious elementary bodies in Chlamydia trachomatis, Proc. Natl. Acad. Sci. USA 2011, 108(25): 10284-10289.
  12. Xiaofei Liang, Chuljin Lee, Xin Chen, Hak Suk Chung, Daina Zeng, Chirstian R. H. Raetz, Yaoxian Li, Pei Zhou*, Eric J. Toone*, Synthesis, Structures and Antibiotic Activities of LpxC Inhibitors Based on the Diacetylene Scaffold, Bioorganic & Medicinal Chemistry 2011, 19(2)：852-860.
  13. Chul-Jin Lee, Xiaofei Liang, Xin Chen, Daina Zeng, Sang Hoon Joo, Hak Suk Chung, Adam W. Barb, Shauna M. Swanson, Robert A. Nicholas, Yaoxian Li, Eric J. Toone, Christian R.H. Raetz, Pei Zhou*, Species-Specific and Inhibitor-Dependent Conformations of LpxC-Implications for Antibiotic Design, Chemistry & Biology 2011, 18(1): 38-47.
  14. Xiaofei Liang, Yaoxian Li, Wen Peng, Jie Bai, Chaoqun Zhang and Qingbiao Yang*, Efficient method for fabrication of fluorescein derivative/PDAC composite nanofibers and characteristics of their photoluminescent properties, European Polymer Journal 2008, 44(10): 3156-3162.
  15. Jie Bai, Yaoxian Li, Chaoqun Zhang, Xiaofei Liang, Qingbiao Yang*, Preparing AgBr nanoparticles in poly (vinyl pyrrolidone) (PVP) nanofibers, Colloids and Surfaces A: Physicochem. Eng. Aspects 2008, 329(3): 3165-3168.

 

PATENTS

  1. Inventors: Liu Jing, Liu Qingsong, Liang Xiaofei, Wang Beilei, Wang Aoli, Liu Xiaochuan, Chen Cheng, Qi Ziping, Wang Wenchao, Zhao Zheng, Wang Li,  "New class of BCR-ABL's kinase inhibitors", (2015) PCT/CN2015/081220.
  2. Inventors:   Liu Qingsong, Liu Jing, Zhang Xin, Liang Xiaofei, Liu Xiaochuan, Liu Juanjuan, Chen Cheng, Zhao Zheng, Wang Aoli, Wang Wenchao, Wu Hong, Wang Beilei, Wang Li, "New class of PI3K's kinase inhibitors!", (2015) PCT/CN2015/081240. 
  3. 发明名称：一种新型的BCR-ABL激酶抑制剂  发明人：刘静，刘青松，梁小飞，王蓓蕾，王傲莉，刘晓川，陈程，齐紫平，王文超，赵铮，王黎，专利受理号：201510172534.7
  4. 发明名称：一种新型的 PI3K 激酶抑制剂  发明人：刘青松，刘静，张欣，梁小飞，刘晓川，刘娟娟，陈程，赵铮，王傲莉，王文超，吴宏，王蓓蕾，王黎 ， 专利受理号：201410821908.9
  5. Inventors: Yaoxian Li, Guofeng Wei, Qingbiao Yang, ShuoWang, Yu Liu, Fuan Liu, Suoqin Zhang, Hengguo Wang, Xiaofei Liang, “Preparation of 3,4-dihydroxybenzaldehyde by air catalytic oxidation method” 2010, CN 101676253 A 20100324.

 

GRANTS

1. Youth Innovation Promotion Association, CAS, 2016/1-2019/12.
2. National Science Foundation of China, 81402797, Structure-Guided Development of BMX Novel Type II Inhibitors, 2015/01-2017/12.
3. The Major/Innovative Program of Development Foundation of Hefei Center for Physical Science and Technology, 2014FXCX009, 2015/1-2016/12.